Key Points
- Director Elisha Finney sold 1,700 ICU Medical shares for $304,300 at an average price of $179, leaving 4,871 shares; the sale reduced their stake by 25.87%.
- ICU Medical beat quarterly earnings and revenue expectations, reporting EPS of $2.44 versus a $2.14 estimate and revenue of $556.22 million, up 4.4% year over year.
- Analysts rate the stock a consensus Moderate Buy, with an average price target of $195.20; shares traded at $179.27 on Friday.
ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) Director Elisha Finney sold 1,700 shares of the company's stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $179.00, for a total value of $304,300.00. Following the completion of the transaction, the director owned 4,871 shares in the company, valued at approximately $871,909. The trade was a 25.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
ICU Medical Stock Performance
NASDAQ ICUI traded up $1.97 on Friday, hitting $179.27. 195,454 shares of the stock traded hands, compared to its average volume of 278,884. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.19 and a current ratio of 2.37. The business's fifty day moving average is $163.72 and its two-hundred day moving average is $149.91. ICU Medical, Inc. has a 12 month low of $113.37 and a 12 month high of $192.85. The firm has a market capitalization of $4.48 billion, a price-to-earnings ratio of 75.01, a PEG ratio of 2.23 and a beta of 0.88.
ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.30. ICU Medical had a return on equity of 8.40% and a net margin of 2.76%. The firm had revenue of $556.22 million for the quarter, compared to analyst estimates of $552.03 million. During the same period in the previous year, the company posted $2.03 earnings per share. The business's revenue was up 4.4% on a year-over-year basis. As a group, equities analysts anticipate that ICU Medical, Inc. will post 7.22 EPS for the current fiscal year.
Hedge Funds Weigh In On ICU Medical
A number of large investors have recently modified their holdings of ICUI. Squarepoint Ops LLC purchased a new position in ICU Medical during the second quarter valued at approximately $3,744,000. Bank of America Corp DE bought a new stake in ICU Medical during the 2nd quarter worth approximately $54,059,000. Legal & General Group Plc purchased a new stake in ICU Medical in the 2nd quarter worth approximately $8,444,000. Reinhart Partners LLC. purchased a new stake in ICU Medical in the 2nd quarter worth approximately $46,148,000. Finally, Edgestream Partners L.P. bought a new position in ICU Medical in the 1st quarter valued at $965,000. 96.10% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
ICUI has been the subject of several recent research reports. BTIG Research lifted their price objective on ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Wall Street Zen raised shares of ICU Medical from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. KeyCorp increased their target price on shares of ICU Medical from $187.00 to $189.00 and gave the stock an "overweight" rating in a research report on Friday, November 6th. Piper Sandler lifted their target price on shares of ICU Medical from $195.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, November 6th. Finally, Weiss Ratings raised shares of ICU Medical from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, ICU Medical currently has a consensus rating of "Moderate Buy" and an average target price of $195.20.
View Our Latest Report on ICUI
ICU Medical Company Profile
(
Get Free Report)
ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
